Chiusura precedente | 27,82 |
Aperto | 27,90 |
Denaro | 27,96 x 700 |
Lettera | 27,99 x 700 |
Min-Max giorno | 27,60 - 28,00 |
Intervallo di 52 settimane | 25,92 - 35,76 |
Volume | |
Media Volume | 2.745.059 |
Capitalizzazione | 16,716B |
Beta (5 anni mensile) | 0,45 |
Rapporto PE (ttm) | 11,06 |
EPS (ttm) | 2,53 |
Prossima data utili | 09 mag 2024 |
Rendimento e dividendo (futuro) | 0,84 (3,02%) |
Data ex dividendo | 16 mag 2024 |
Stima target 1A | 45,50 |
NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2023 financial results on Wednesday, November 8, 2023 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Conference Call Information Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/news-and-events/events to obtain conference
NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Eric Schneider as Senior Vice President, Chief Technology Officer. Eric will also join Royalty Pharma’s Senior Leadership Committee. Eric joins Royalty Pharma from Verisk, a global leader in data-driven analytic insights and solutions, where he was a Senior Vice President, Chief Data Officer and Chief Technology Officer, and a member of the Executive Leadership Team. During his tenur
• Proceeds to support continued development and commercialization of Endocrine Rare Disease products and general corporate purposes NEW YORK and COPENHAGEN, Denmark, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Ascendis Pharma A/S (Nasdaq: ASND) today announced that Royalty Pharma has entered into a $150 million capped synthetic royalty funding agreement with Ascendis based on U.S. net Skytrofa revenue. “This transaction reflects the significant value of Skytrofa. We